SecBot SecBot

FBLG

FibroBiologics, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001958777 Biotech & Drug Discovery
$0.9498 −0.00 (−0.02%)
Oct 26 4:00 PM ET · prev $0.9500
Market cap
$6.9M
Nano cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$12.50
+1216% · range $6.00–19.00
Next earnings
Nov 17
in 22 days · EPS est. −$0.63
1 year
−89.0%
from $8.66 · Oct 27
30 days
−30.2%
from $1.36
52-week range
$0.6270–8.70
−89% from high · low Jul 27
Avg volume 20D
142.0K
Oct 22 spike 398.5K
Short interest
522.1K
≈7.8% of shares · −21.1%
Days to cover
3.8
at average volume
Insider net
+$73.0K
4 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
SecBot read BEARISH 6 reports · 90 days
Balance 3 bearish · 0 bullish · 3 neutral oldest → newest, height = score
Avg score ·High conf. 4/6 ·Next Earnings date, Nov 17, 2026
Strongest BEARISH FibroBiologics issued a $1.2M convertible debenture to Peak One Opportunity Fund at a 15% original issue…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    4 insiders bought $73.0K. No open-market sales.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 3 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • EstimatesRISING

    Current-quarter EPS estimate −$0.770 → −$0.630 over 90 days. 1 up, 0 down in 30 days.

  • Short sellersCOVERING

    Short interest −21.1% to 522.1K shares. 3.8 days to cover, ≈7.8% of shares.

  • TrendDOWNTREND

    28% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
VANGUARD CAPITAL MANAGEMENT LLCTRIM27,769$26.3K
BlackRock, Inc.TRIM18,238$17.3K
OSAIC HOLDINGS, INC.DOUBLED2,404$2.3K
UBS Group AGNEAR_EXIT1,073$1.0K
ROYAL BANK OF CANADADOUBLED1,522$1.0K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 2 analysts

Price is below the lowest target. Median implies +1216%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 4, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
May 4, 2026Maxim Group
DOWNGRADE
DOWNGRADEHold

Insider ledger

Form 4
$73.0K
bought · 4 insiders
$0
sold · 0 insiders
DateInsiderTypeValue
Sep 15, 2026
Khoja Hamid
Chief Scientific Officer
AWARD$500.0K
Sep 15, 2026
Khoja Hamid
Chief Scientific Officer
AWARD298,508 sh
Jun 23, 2026
Niklas Victoria Ninon Olivia
Director
AWARD30,803 sh
Jun 23, 2026
Hoffman Robert E.
Director
AWARD30,803 sh
Jun 23, 2026
Link Matthew
Director
AWARD30,803 sh
Jun 23, 2026
Cilento Richard C. Jr.
Director
AWARD30,803 sh
May 4, 2026
GARCIA RUBEN A
General Counsel
AWARD61,607 sh
May 4, 2026
Davis Jason
Chief Financial Officer
AWARD61,607 sh

Earnings setup

Estimates
Nov 17
reports in 22 days
−$0.63
EPS estimate, this quarter
+18%
estimate change, 90 days
1↑ 0↓
revisions, 30 days
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.63-$0.63–-$0.63+33.0%$0.00
Next Q-$0.63-$0.63–-$0.63+33.0%$0.00
Current FY-$3.00-$3.00–-$3.00+25.2%$0.00
Next FY-$3.25-$3.25–-$3.25+27.6%$0.00

Short side

FINRA· Sep 30, 2026
522,114
shares short
-21.1%
vs prior settlement
3.8
days to cover
≈7.8%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 20, 2026 SEC
The SEC declared effective FibroBiologics' shelf registration (File No. 333-284077) on October 19, 2026, under the…
EFFECT — Impact 5/10
Oct 20, 2026 SEC
The SEC declared effective FibroBiologics' registration statement on Form S-1 (File No. 333-280303) on October 19…
EFFECT — Impact 5/10
Oct 8, 2026 SEC
FibroBiologics issued a $1.2M convertible debenture to Peak One Opportunity Fund at a 15% original issue discount…
8-K — Impact 6/10
Sep 15, 2026 Insider
Khoja Hamid was granted 298,508 shares
Chief Scientific Officer @ $1.68 ($500.0K)
Sep 15, 2026 Insider
Khoja Hamid was granted 298,508 shares
Chief Scientific Officer
Aug 25, 2026 Listing status
Listing Status: FBLG — Normal (was Deficient)
FibroBiologics, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Jun 30, 2026 Inst.
VANGUARD CAPITAL MANAGEMENT LLC — TRIM
27,769 shares ($26.3K)
Jun 30, 2026 Inst.
BlackRock, Inc. — TRIM
18,238 shares ($17.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 17, 2026
Earnings date
FBLG Q3 2026 Earnings Scheduled — 2026-11-17
Recent
Aug 25, 2026
Listing
Listing Status: FBLG — Normal (was Deficient)
FibroBiologics, Inc. - Common Stock | Nasdaq Financial Status Indicator D → N
Aug 24, 2026
Press release
FibroBiologics Appoints Leigh Steinberg to Board of Directors
Legendary Sports Agent, Attorney, and Longtime Advocate for Human Longevity and Brain Health Joins Board HOUSTON, Aug. 24, 2026 /PRNewswire/…
Aug 18, 2026
Press release
FibroBiologics Announces Chondrocyte Spheroids Demonstrate Cartilage Repair in Preclinical Study of Degenerative Joints
Animal trials show cartilage repair within four weeks following a single injection of chondrocyte spheroids HOUSTON, Aug. 18, 2026 /PRNewswire/…
Jul 31, 2026
Earnings
FibroBiologics Reports Second Quarter 2026 Financial Results; Progresses Clinical Trial Evaluating Lead Wound Care Candidate
- First patients dosed in phase 1/2 clinical trial evaluating CYWC628 in diabetic foot ulcers - On track for interim results reporting in 2H 2026…
Jul 30, 2026
Listing
Listing Status: FBLG — Deficient (was Normal)
FibroBiologics, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D

SecBot reports

17 filings · 5 press releases · 1 bullish · 6 bearish · 10 neutral
All FBLG filing & press-release reports (22)